PopulationsHumans20,031 patientsCohort study

Clinical outcomes associated with glucagon-like peptide-1 receptor agonist therapy in patients with peripheral artery disease and diabetes

Figure 1 from Diabetes & Metabolism — Figure 1Khadija et al.

Diabetes & Metabolism

The paper

Haitham Abu Khadija, Mohammad Alnees, Ali Abdullah,

Kareem Ibraheem, Taha Z Makhlouf, Ramon Cohen, Duha Najajra, Orit Twito, Tal Schiller,

Hebrew University of Jerusalem

Diabetes & Metabolism · 24 Sep 2026

doi.org/10.1016/j.diabet.2026.101794 PubMed 42785671

SGLT2 inhibitors link to lower dementia risk than GLP-1 drugs
Diabetes & Vascular Disease Research · 4 Oct 2026
SGLT2 inhibitors match GLP-1 drugs for overall kidney outcomes
Clinical Journal of the American Society of Nephrology · 4 Oct 2026
GLP-1 agonists linked to lower dementia risk after COVID-19
Drug Design, Development and Therapy · 5 Oct 2026
GLP-1 drugs added to SGLT2 inhibitors linked to lower kidney risk
Diabetes, Obesity & Metabolism · 4 Oct 2026